trial summary · NCT07551596
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Colorectal Adenocarcinoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with detectable circulating tumor (ct) deoxyribonucleic acid (DNA) in the blood. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving botensilimab and balstilimab may be an effective combination to remove any remaining microscopic cancer cells in the bloodstream in patients with stage II/III colorectal adenocarcinoma. In addition, clearing the ctDNA from the blood may serve as an early indicator of treatment response.
Source record: https://clinicaltrials.gov/study/NCT07551596
Facts
| registry id | NCT07551596 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Colorectal Adenocarcinoma |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 20 |
| start date | 2027-05-25 |
| primary completion | 2029-08-28 |
| completion | 2029-08-28 |
| results posted | not reported |
Conditions
- Colorectal Adenocarcinoma
- Stage II Colorectal Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
Interventions
- Balstilimab
- Biopsy Procedure
- Biospecimen Collection
- Botensilimab
- Radiographic Examination
Countries
- United States
Intervention types: BIOLOGICAL, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.